Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells for High-Risk/Refractory/Relapsed AML
NCT05272293Phase 2Recruiting
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- Start
- Nov 2021
- Primary completion
- Dec 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical natural killer cells in acute myeloid leukemia (AML), sponsored by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology. Started Nov 2021; status: recruiting.
02
Drugs
haploidentical natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05272293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272293.